oxidopamine has been researched along with Affective Disorders in 4 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Parkinson's disease is a neurodegenerative disease characterized by progressive dopaminergic neuronal loss." | 1.72 | Pharmacological Rescue with SR8278, a Circadian Nuclear Receptor REV-ERBα Antagonist as a Therapy for Mood Disorders in Parkinson's Disease. ( Choe, HK; Choe, Y; Choi, JW; Choi, M; Jang, S; Kim, D; Kim, J; Kim, K; Moon, C; Park, I; Park, SH; Sun, W, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, J | 1 |
| Park, I | 1 |
| Jang, S | 1 |
| Choi, M | 1 |
| Kim, D | 1 |
| Sun, W | 1 |
| Choe, Y | 1 |
| Choi, JW | 1 |
| Moon, C | 1 |
| Park, SH | 1 |
| Choe, HK | 1 |
| Kim, K | 1 |
| Carvalho, MM | 1 |
| Campos, FL | 1 |
| Coimbra, B | 1 |
| Pêgo, JM | 1 |
| Rodrigues, C | 1 |
| Lima, R | 1 |
| Rodrigues, AJ | 1 |
| Sousa, N | 1 |
| Salgado, AJ | 1 |
| Petri, D | 1 |
| de Souza Silva, MA | 1 |
| Chao, OY | 1 |
| Schnitzler, A | 1 |
| Huston, JP | 1 |
| Singh, S | 1 |
| Mishra, A | 1 |
| Srivastava, N | 1 |
| Shukla, S | 1 |
4 other studies available for oxidopamine and Affective Disorders
| Article | Year |
|---|---|
Pharmacological Rescue with SR8278, a Circadian Nuclear Receptor REV-ERBα Antagonist as a Therapy for Mood Disorders in Parkinson's Disease.
Topics: Animals; Humans; Isoquinolines; Mice; Mood Disorders; Neurodegenerative Diseases; Nuclear Receptor S | 2022 |
Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.
Topics: Adrenergic Agents; Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Bupropion | 2013 |
Serotonergic interaction between medial prefrontal cortex and mesotelencephalic DA system underlies cognitive and affective deficits in hemiparkinsonian rats.
Topics: Adrenergic Agents; Animals; Cognition Disorders; Disease Models, Animal; Excitatory Amino Acid Agoni | 2015 |
MK-801 (Dizocilpine) Regulates Multiple Steps of Adult Hippocampal Neurogenesis and Alters Psychological Symptoms via Wnt/β-Catenin Signaling in Parkinsonian Rats.
Topics: Adaptation, Ocular; Animals; beta Catenin; Cell Proliferation; Disease Models, Animal; Dizocilpine M | 2017 |